Everstar Asset Management LLC Has $770,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Everstar Asset Management LLC trimmed its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 46.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 216,223 shares of the company’s stock after selling 183,902 shares during the quarter. Everstar Asset Management LLC’s holdings in Aquestive Therapeutics were worth $770,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. New York State Common Retirement Fund raised its position in Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares in the last quarter. PKS Advisory Services LLC bought a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $63,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Aquestive Therapeutics in the 4th quarter worth approximately $69,000. Intech Investment Management LLC acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $90,000. Finally, BNP Paribas Financial Markets grew its position in Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after acquiring an additional 13,481 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

AQST opened at $3.02 on Monday. The stock has a market capitalization of $298.59 million, a P/E ratio of -6.71 and a beta of 2.76. The company’s 50 day simple moving average is $2.99 and its 200-day simple moving average is $3.94. Aquestive Therapeutics, Inc. has a one year low of $2.24 and a one year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital cut their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday, March 10th. Finally, Raymond James set a $7.00 price target on Aquestive Therapeutics in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.